Vijoice Works by Blocking the Overactive Enzyme That Causes Tissue Overgrowth

Vijoice (Alpelisib) treats PIK3CA-Related Overgrowth Spectrum (PROS) by blocking PI3K-alpha, the specific enzyme that's overactive due to a PIK3CA gene mutation, which stops the abnormal signal telling cells to keep growing.

If that sounds like a lot of medical jargon, don't worry. This article breaks down exactly what Vijoice does in your body, how long it takes to work, and what makes it different from other treatments—all in plain English.

What Vijoice Does in Your Body

The Problem: A Broken Growth Signal

Think of your cells like a factory. They need instructions to know when to grow, when to stop, and when to rest. One of the key "instruction manuals" for cell growth involves an enzyme called PI3K-alpha (phosphatidylinositol 3-kinase alpha).

In people with PROS, there's a typo in the PIK3CA gene—the gene that makes the PI3K-alpha enzyme. This typo (mutation) makes the enzyme stuck in the "on" position, like a growth switch that never turns off. The result? Cells in affected tissues keep growing when they shouldn't, causing overgrowth of bones, fat, blood vessels, lymphatic tissue, or skin.

The Solution: Turning Down the Volume

Vijoice is a selective PI3K inhibitor. Here's what that means in simple terms:

• PI3K inhibitor = it blocks the PI3K enzyme
• Selective = it specifically targets the PI3K-alpha version (the one that's broken in PROS), rather than blocking all types of PI3K

Imagine the overactive PI3K-alpha enzyme is like a radio stuck on full volume. Vijoice doesn't smash the radio—it turns the volume dial back down to a normal level. By blocking the overactive PI3K-alpha, Vijoice reduces the "grow, grow, grow" signal that's causing tissue overgrowth.

This doesn't reverse overgrowth that's already happened (existing bone growth, for example, won't shrink). But it can:

• Slow or stop further overgrowth
• Reduce the size of soft tissue overgrowth (like vascular malformations)
• Improve symptoms and quality of life
• Potentially reduce the need for surgical interventions

A Closer Look at the PI3K Pathway

For those who want a bit more detail: PI3K-alpha is part of a larger signaling chain inside cells called the PI3K/AKT/mTOR pathway. This pathway controls cell growth, survival, and metabolism. When PI3K-alpha is overactive, it sends excessive signals down this chain, leading to uncontrolled cell proliferation.

Vijoice blocks PI3K-alpha at the top of this chain, which dampens the entire cascade of growth signals downstream. This is why it's effective—it goes after the root cause of the overgrowth rather than trying to manage symptoms one at a time.

How Long Does Vijoice Take to Work?

This depends on what you're measuring and the severity of your condition:

• Soft tissue changes: Some patients notice improvements in soft tissue overgrowth (reduced swelling, decreased pain) within the first few weeks to months of treatment.
• Vascular malformations: Improvements in vascular lesions have been documented in clinical studies, though the timeline varies by individual.
• Functional improvements: Things like reduced pain, improved mobility, or decreased bleeding from vascular malformations may improve gradually over the first several months.
• Full assessment: Your doctor will typically evaluate your response after 24 weeks (about 6 months) to determine whether to continue at the starting dose, increase the dose, or adjust the treatment plan.

It's important to set realistic expectations. Vijoice is a long-term treatment—most patients take it continuously. It's managing an ongoing genetic condition, not curing it.

How Long Does Vijoice Last in Your System?

Vijoice is taken once daily, and the medication needs to be taken consistently to maintain its effect. If you stop taking Vijoice, the PI3K-alpha enzyme will become overactive again, and overgrowth may resume.

This is why consistent dosing—once daily with food, at the same time each day—is so important. Missing doses can reduce the medication's effectiveness. If you miss a dose, take it with food within 9 hours of the regular time. If more than 9 hours have passed, skip that day's dose and take the next one at your usual time.

What Makes Vijoice Different from Similar Medications?

Vijoice vs. Sirolimus (Rapamune)

Before Vijoice was approved, the most commonly used systemic treatment for PROS was Sirolimus (Rapamune), an mTOR inhibitor used off-label. Here's how they compare:

• Target: Vijoice blocks PI3K-alpha (upstream in the signaling pathway). Sirolimus blocks mTOR (downstream in the same pathway).
• Specificity: Vijoice is more targeted—it goes after the exact enzyme that's overactive due to the PIK3CA mutation. Sirolimus blocks mTOR more broadly, which can affect other cellular processes.
• FDA approval: Vijoice is FDA-approved for PROS. Sirolimus is used off-label (approved for preventing organ transplant rejection, not PROS).
• Analogy: If the overgrowth pathway is a river, Vijoice builds a dam near the source, while Sirolimus tries to block the flow further downstream. Blocking closer to the source is generally more effective at controlling the problem.

Vijoice vs. Piqray

Vijoice and Piqray are actually the same active ingredient—Alpelisib—made by the same manufacturer (Novartis). The difference is the approved use:

• Vijoice: Approved for severe PROS (overgrowth spectrum)
• Piqray: Approved for PIK3CA-mutated, HR+/HER2- advanced breast cancer

The dosing is different (PROS doses are generally lower than cancer doses), and the patient populations are different, but the underlying mechanism is the same: blocking overactive PI3K-alpha.

Vijoice vs. Miransertib

Miransertib is an AKT inhibitor currently under investigation for PIK3CA-related disorders. While Vijoice blocks PI3K-alpha, Miransertib targets AKT—the next step down in the same signaling pathway. Think of it as a backup option that blocks the pathway at a different point. It's not yet FDA-approved but is being studied in clinical trials.

Final Thoughts

Vijoice works by going directly after the root cause of PROS overgrowth: the overactive PI3K-alpha enzyme caused by PIK3CA gene mutations. By selectively blocking this enzyme, it turns down the growth signal that drives tissue overgrowth, offering patients a targeted treatment that addresses the biological source of their condition.

Understanding how your medication works can help you stay motivated with daily dosing and have better conversations with your healthcare team. For more on what to expect during treatment, see our guides on Vijoice side effects and what is Vijoice: uses, dosage, and what you need to know.